Previous 10 | Next 10 |
Named Patient Program (NPP) enables physicians to prescribe the Company's novel Mazindol Extended-Release (ER) formulation to patients who have failed approved therapies Product sales through the NPP are expected to be revenue-generating, with patient access anticipated to begin in Q2 ...
Major drug companies, including leading COVID-19 vaccine developers, have joined efforts to discover a potential treatment for long COVID, a condition affecting over 100 million people globally. According to the World Health Organization (WHO), more than 100 million people suffer from long CO...
ZURICH, SWITZERLAND / ACCESSWIRE / March 25, 2022 - NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous sys...
Gainers: Sonnet BioTherapeutics Holdings (NASDAQ:SONN) +92%. Zhihu (NYSE:ZH) +80%. Kingsoft Cloud (NASDAQ:KC) +74%. KE Holdings (NYSE:BEKE) +61%. Dingdong Limited (NYSE:DDL) +58%. VNET Group (NASDAQ:VNET) +57%. American Rebel (NASDAQ:AREB) +61%. JOYY (NASDAQ:YY) +53%. Chindata Group (NASDAQ:C...
Gainers: Zai Lab (NASDAQ:ZLAB) +27%. 111 (NASDAQ:YI) +26%. LianBio (NASDAQ:LIAN) +22%. BeiGene BGNE +20%. Palisade Bio PALI +10%. Losers: Talis Biomedical (NASDAQ:TLIS) -42%. Incannex Healthcare (NASDAQ:IXHL) -32%. NLS Pharmaceutics NLSP&...
On Wednesday, Swiss clinical-stage biopharmaceutical company, NLS Pharmaceutics (NASDAQ:NLSP), announced interim top-line data from a Phase 2a clinical trial designed to evaluate its lead product candidate Quilience (Mazindol ER) in narcolepsy. The company plans to enroll 60 patients in the U...
Clinically meaningful results with Mazindol ER exhibiting a 39% reduction in ESS from baseline (-4.3 points placebo-adjusted); confirms statistical powering of the ongoing Phase 2a trial Safety and tolerability data consistent with prior mazindol clinical trials, no reported SAEs ...
Penny stocks can be hot or cold, depending on who you ask. But in the stock market today, there’s no shortage of big movers. Maybe they jump for a day or go on to rally for weeks; the potential for penny stocks to make you money is undeniable. Assuming you’ve got a sto...
ZURICH, SWITZERLAND / ACCESSWIRE / February 25, 2022 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP) (Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central...
ZURICH, SWITZERLAND / ACCESSWIRE / February 11, 2022 / NLS Pharmaceutics Ltd. ( NASDAQ:NLSP ) (NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central...
News, Short Squeeze, Breakout and More Instantly...
NLS Pharmaceutics Ltd. Company Name:
NLSP Stock Symbol:
NASDAQ Market:
NLS Pharmaceutics Ltd. Website:
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 1.3% to $111.59 on volume of 240,827,673 shares Lipella Pharmaceuticals Inc. (LIPO) rose 122.5% to $0.8992 on volume of 193,926,302 shares PROSHARES TRUST (SQQQ) fell 0.5% to $9.05 on volume of 150,372,371...
The proposed transaction will create a Nasdaq-traded, biotechnology company with product candidates in advanced stages of clinical development and focused on advancing Kadimastem's allogeneic cell therapy platform Each of Kadimastem and NLS Pharmaceutics has received commitments of support f...
A look at the top 10 most actives in the United States Innovative Eyewear Inc. (LUCY) rose 78.0% to $0.58749 on volume of 130,454,575 shares Ocean Power Technologies Inc. (OPTT) rose 29.6% to $0.2073 on volume of 51,927,154 shares Cosmos Health Inc. (COSM) rose 64.9% to $1.12 on volume of...